Cargando…
Commercially Available Flavonols Are Better SARS-CoV-2 Inhibitors than Isoflavone and Flavones
Despite the fast development of vaccines, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is still circulating and generating variants of concern (VoC) that escape the humoral immune response. In this context, the search for anti-SARS-CoV-2 compounds is still essential. A class of natur...
Autores principales: | Chaves, Otávio Augusto, Fintelman-Rodrigues, Natalia, Wang, Xuanting, Sacramento, Carolina Q., Temerozo, Jairo R., Ferreira, André C., Mattos, Mayara, Pereira-Dutra, Filipe, Bozza, Patrícia T., Castro-Faria-Neto, Hugo Caire, Russo, James J., Ju, Jingyue, Souza, Thiago Moreno L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9324382/ https://www.ncbi.nlm.nih.gov/pubmed/35891437 http://dx.doi.org/10.3390/v14071458 |
Ejemplares similares
-
Apixaban, an orally available anticoagulant, inhibits SARS-CoV-2 replication and its major protease in a non-competitive way
por: Chaves, Otávio Augusto, et al.
Publicado: (2022) -
Fluorine Atoms on C(6)H(5)-Corrole Affect the Interaction with M(pro) and PL(pro) Proteases of SARS-CoV-2: Molecular Docking and 2D-QSAR Approaches
por: Chaves, Otávio Augusto, et al.
Publicado: (2022) -
Agathisflavone, a natural biflavonoid that inhibits SARS-CoV-2 replication by targeting its proteases
por: Chaves, Otávio Augusto, et al.
Publicado: (2022) -
Combination of Antiviral Drugs to Inhibit SARS-CoV-2 Polymerase and Exonuclease as Potential COVID-19 Therapeutics
por: Wang, Xuanting, et al.
Publicado: (2021) -
Combination of antiviral drugs inhibits SARS-CoV-2 polymerase and exonuclease and demonstrates COVID-19 therapeutic potential in viral cell culture
por: Wang, Xuanting, et al.
Publicado: (2022)